Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

§ 01 Executive Snapshot

• What: Inhibrx announced updated interim data from its Phase 1/2 study of ozekibart (INBRX-109) in colorectal cancer.
• Who: Inhibrx Biosciences, Inc. (Nasdaq: INBX) and its CEO Mark Lappe.
• Why it matters: The results suggest potential for deeper responses and broader application of ozekibart in cancer treatment, signaling significant advancements in therapeutic options for challenging cancers.

§ 02 Key Developments

• As of April 10, 2026, 70% of the 45 evaluable patients in the CRC cohort received ozekibart as a fourth-line therapy.
• 80% of these patients had previously progressed on irinotecan-based regimens.
• Inhibrx plans to meet with the FDA in the second half of 2026 to discuss a first-line registrational trial in CRC and potential accelerated regulatory pathways.

§ 03 Strategic Context

• Ozekibart has been granted Fast Track and orphan drug designations by the FDA for chondrosarcoma, indicating its significance in addressing unmet medical needs.
• The recent positive outcomes in trials for ozekibart represent a breakthrough in treatment options for colorectal cancer, a disease with limited approved therapies.

§ 04 Strategic Implications

• Immediate implications include potential FDA approval pathways that could expedite ozekibart's availability for patients in need of effective treatments.
• Long-term, the success of ozekibart could position Inhibrx as a leader in the biopharmaceutical space for cancer therapies, expanding their market share.

§ 05 Risks & Constraints

• Regulatory hurdles or delays could impact the timeline for ozekibart's approval and commercialization.
• Competition from other biopharmaceutical companies developing similar therapies could affect market positioning and patient access.

§ 06 Watchlist / Forward Signals

• The planned FDA meeting in the second half of 2026 will be a critical milestone for ozekibart's development.
• Future clinical trial results and regulatory decisions will be key indicators of ozekibart's viability and market potential.